Loading...
Loading...
The FDA has voted 10-5 in favor of approving Human Genome Sciences
HGSI Benlysta, saying the drug is effective in treatment.
Shares were halted all day, before the announcement of the panel's recommendation.
The last trade for HGSI was $25.88.
Human Genome Sciences Inc. has drugs in its pipeline that include novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in